ANAB has a history of major successes under its belt. Among these, it discovered the anti pd-1 molecule, dostarlimab, which it licensed to GSK. Dostarlimab was approved as Jemperli for the ...

Anaptys has cash, cash equivalents and investments greater than $420 million as of December 31, 2024, and anticipates receipt of a $75 million commercial sales milestone payment from GSK in 2025 or ...

In a report released on March 24, David Risinger from Leerink Partners maintained a Buy rating on AnaptysBio (ANAB – Research Report). The company’s shares closed yesterday at $18.19.

ANAB opened at $18.44 on Wednesday. AnaptysBio has a 12 month low of $12.21 and a 12 month high of $41.31. The business’s 50-day moving average price is $16.95 and its 200-day moving average ...

AnaptysBio, Inc. has announced a Stock Repurchase Plan allowing for the buyback of up to $75 million of its common stock. As of the end of 2024, the company reports having over $420 million in ...

Ratings for AnaptysBio ANAB were provided by 8 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. Summarizing their recent assessments, the table below ...

AnaptysBio (NASDAQ:ANAB – Get Free Report)‘s stock had its “neutral” rating reaffirmed by stock analysts at HC Wainwright in a research report issued on Tuesday,Benzinga reports.

AnaptysBio shares rose 7.2% on a share-repurchase program authorized to buy back up to $75 million of the company's common stock. Shares were recently trading around $18.31. The stock is down 15% ...

AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its ...